Fan, F <br/><br/>
Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.  [electronic resource] 

 -  British journal of cancer  Apr 2011 
 - 1270-7 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2011.81  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacology<br/>Bevacizumab<br/>Carcinoma--pathology<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Colorectal Neoplasms--pathology<br/>Drug Resistance, Neoplasm--drug effects<br/>HCT116 Cells<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Neoplasm Metastasis<br/>Signal Transduction--drug effects<br/>Time Factors<br/>Transplantation, Heterologous